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Correlation of monocyte/HDL ratio (MHR) with 
inflammatory parameters in obese patients diagnosed 
with polycystic ovary syndrome
Dilsad Herkiloglu , Sefik Gokce
Istanbul Yeni Yuzyil University Department Of Obstetrics And Gynecology, Istanbul, Turkey
ABSTRACT
Objectives: Monocyte/high density lipprotein (HDL) ratio (MHR) has been reported to be associated with obesity and 
polycystic ovarian syndrome (PCOS). In this study, it was aimed to evaluate whether there is a relationship between PCOS 
and MHR and inflammatory parameters, to investigate the relationship level of MHR and lymphocyte/monocyte ratio (LMR), 
which are easily accessible inflammatory and oxidative stress markers, with obese women with PCOS, and to determine 
the usability of MHR as a predictive marker for PCOS.
Material and methods: The study included 64 PCOS-patients who were admitted to Gynecology clinics and 52 healthy 
women. 
Results: The mean MHR (12.5 ± 4.6) in the PCOS group was significantly higher than the control group (10.4 ± 4.0) (p = 0.01). 
In the examination performed by combining the groups PCOS and obesity status, the mean MHR value in the PCOS-obese 
group was significantly higher than all the other groups (p = 0.004). In the ROC analysis, the threshold value of 10.1 for MHR 
was found to have a sensitivity of 84.8% and specificity of 58.5% in determining the association between PCOS and obesity 
(AUC: 0.721; p < 0.001; LB: 0.628; UB: 0.814; CI 95%). Accordingly, the rate of those with MHR level of 10.1 and above was 
significantly higher in the PCOS group compared to the control group (67.2% vs 40.4%) (p = 0.001). In the logistic regression 
analysis, the determination is increased by 3,026 times (odds ratio; 1.401–6.535) in predicting the presence of PCOS in those 
with MHR value of 10.1 and above, and 7,576 times (Odds ratio; 2.652–21.646) in predicting the presence of PCOS + obesity. 
was found to be. Correlation analysis in PCOS patients revealed that the MHR value was negatively correlated with age 
(p = 0.001; r = –0.412), LMR (p = 0.003; r = –0.377), and total cholesterol [p = 0.018; correlation coefficient (r) = –0.302].
Conclusions: This study findings showed that MHR level is significantly related to PCOS, and especially MHR values above 
10.1 may be a significant predictive marker for PCOS. Our study findings also show that an association of PCOS and obesity 
is a very important trigger on MHR.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a disorder charac-
terized by impaired hormone balance, polycystic ovaries and 
ovulation disorders disorder, such as hyperandrogenism. 
Impaired hormone balance in PCOS affects many systems, 
causing a wide variety of complications. It has been reported 
that the frequency of obesity increases in women with PCOS, 
and that PCOS can cause dyslipidemia and cardiovascular 
diseases more frequently in these patients [1, 2].
Monocytes are one of the main structures in the im-
mune system. It has been suggested that monocytes play 
a role in atherosclerosis. High-density lipoproteins (HDL) 
are known to play a role in the prevention of atherosclerosis 
and cardiovascular diseases. It has been reported that HDL 
also affects the functions of monocytes and functions to 
prevent monocytes from functioning in atherosclerosis and 
cardiovascular disease [3–5]. In this context, the monocyte/ 
/HDL ratio (MHR) has been shown to increase in many 
diseases, especially in atherosclerosis and cardiovascular 
diseases, and it has been shown that MHR can be used as 
a predictive marker in many disorders [5, 6].
It has been reported that MHR is associated with meta-
bolic syndrome, obesity and PCOS [7, 8]. However, there 
are very few studies showing a direct relationship between 
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MHR with PCOS and obesity. It has been proven that obesity, 
which has an important place in cardiovascular diseases, is 
significantly and independently associated with high MHR 
and low LMR levels [9]. In this study, we aimed to evaluate 
whether there is a relationship between PCOS and MHR and 
other inflammatory parameters, to investigate the relation-
ship of MHR and LMR that are easily obtained inflammatory 
and oxidative stress markers, with obesity in women with 




The study included 64 patients diagnosed with PCOS 
and 52 healthy women who presented to the Gynecology 
and Obstetrics clinics of our tertiary hospital. The study 
was approved by the ethics committee in accordance with 
the requirements of the Declaration of Helsinki. Informed 
consent was obtained from all participants. PCOS was di-
agnosed using Rotterdam criteria [10]. According to these 
criteria; oligomenorrhea (where menstrual cycles occur for 
more than 35 days) or amenorrhea (where menstrual cycles 
occur within at least six months intervals) is defined as 
oligoovulation. In addition, the presence of hirsutism, one 
of the hyperandrogenism findings, was evaluated using 
the Ferriman-Gallwey scoring system [11]. Physical and gy-
necological examinations, pelvic ultrasounds and peripheral 
venous blood sampling were performed on the second or 
third day of a participant’s menstrual cycles. All women were 
examined and pelvic ultrasound scans were performed by 
the same gynecologist using a 7.0 MHz vaginal transducer 
(Voluson 730, GE Healthcare, USA).
Patients who received medications for some diseases 
such as Cushing syndrome, congenital adrenal hyperpla-
sia, androgen-secreting tumors, oral contraceptives, an-
tilipidemic and/or antihypertensive drugs, steroids, diabetic 
drugs, anticoagulants or antiplatelet drugs were excluded 
from the study.
After one night fasting, blood samples of the patients 
were taken from the antecubital veins. For serum, biochemi-
cal and hormonal evaluation; complete blood counts were 
measured using fluorescent flow cytometry or electrical 
impedance method. Serum levels of follicle-stimulating 
hormone (FSH), luteinizing hormone (LH), oestradiol (E2), 
thyroid-stimulating hormone (TSH), antimullient hormone 
and total testosterone were determined using commer-
cially available enzyme-dependent immunosorbent assay 
(ELISA) kits (eBioscience). Glucose, insulin, total cholesterol, 
low density lipoprotein (LDL) cholesterol and high density 
lipoprotein (HDL) cholesterol levels were measured with 
AutoAnalyzer. Those with a BMI value ≥ 25 kg/m² were 
considered obese [12]. The patients were divided into four 
groups according to the presence or absence of PCOS and 
obesity [8]. Accordingly, 38 obese patients diagnosed with 
PCOS and 35 obese patients without a diagnosis of PCOS 
were included in the study.  
The LMR value was calculated by dividing the absolute 
lymphocyte by the absolute number of monocytes. The 
basic MHR was calculated by dividing the number of mono-
cytes by the HDL-C level.
Depending on the result of the receiver operating char-
acteristic (ROC) analysis performed on the MHR value, the 
participants were divided into two groups according to 
a 10.1 cut-off value.
Statistical analysis
All statistical analyzes were performed using SPSS ver-
sion 25.0 software (IBM SPSS, Chicago, IL, USA). Descriptive 
data are given as numbers and percentages. Comparisons 
between the groups were made with Pearson’s Chi Square 
test and Fisher’s Exact Test for the categorical variables. Nor-
mality of the continuous variables was evaluated with the 
Kolmogorov-Smirnov Test. The differences between the 
groups in terms of continuous variables were analyzed us-
ing Student’s t Test, and the comparison of mean values 
between multiple groups by variance analysis. The relation-
ships between continuous variables were tested using Spear-
man’s correlation analysis. The capacity of MHR to predict the 
association of PCOS and obesity was analyzed using ROC 
curve analysis. Risk coefficient of categorical variables was 
evaluated by logistic regression analysis and given as “odds 
ratio”. The results were evaluated within the 95% confidence 
interval, and p < 0.05 values were considered statistically sig-
nificant. Bonferroni correction was made where appropriate.
RESULTS
The mean age was 26.5 ± 3.8 years (range: 20–34 years) 
in the PCOS group, 27.8 ± 3.6 (range: 21–34 years) in the 
control group, and there was no significant difference 
between both groups in terms of mean age (p = 0.077). 
The mean MHR (12.5 ± 4.6) in the PCOS group was statisti-
cally significantly higher than the control group (10.4 ± 4.0) 
(p = 0.01) (Tab. 1).
In the examination performed by combining PCOS and 
obesity status of the groups, the mean MHR value was sig-
nificantly higher in the PCOS-obese group compared to all 
other groups (p = 0.004) (Tab. 2, Fig. 1).
In the ROC analysis, cut-off value of 10.1 for MHR was found 
to have a sensitivity of 84.8% and a specificity of 58.5% in deter-
mining the association between PCOS and obesity [area under 
curve (AUC): 0.721; p < 0.001; lower bound (LB): 0.628; upper 
bound (UB): 0.814; confidence interval (CI) 95%] (Fig. 2). Ac-
cordingly, the rate of those with a MHR level ≥ 10.1 was signifi-
cantly higher in the PCOS group compared to the control group 
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Inflammation and lipid accumulation are two indicators 
of atherosclerosis. In addition to being localized, inflam-
mation is a systemic process with increased levels of me-
diator molecules. Monocytes are a resource for structures 
involved in the proinflammatory process. Monocytes play 
a role in the first stage of progression of atherosclerosis. They 
take part in the immune-mediated process, and bind to 
adhesion molecules in the damaged vascular endothelium, 
migrate to the subendothelial cavity, where they mature 
and differentiate into macrophages [5, 15]. Modified LDLs 
in atherosclerosis are taken up by macrophages located 
in the vascular wall, inducing the release of inflammatory 
cytokines. Monocytes also play a role in atherogenesis and 
therefore in the pathogenesis of cardiovascular diseases 
through many different mechanisms [5, 16]. HDL neutralizes 
the proinflammatory effect of monocytes by inhibiting the 
migration of macrophages and LDL oxidation as well as the 
removal of cholesterol from the cells. HDL reduces the con-
tent of F-actin and prevents monocytes from functioning in 
the arterial wall. It also prevents the adhesion of monocytes 
to the endothelial wall [5, 17]. HDL also suppresses activa-
tion of monocytes and transformation of precursor cells 
into monocytes [5]. It has been suggested that the inverse 
of this mechanism, monocyte accumulation and decrease 
in HDL may play a role in atherosclerosis and cardiovascular 
diseases. In this context, it has been stated that HDL plays 
a role in the reduction of atherosclerosis [5, 18, 19].
It was suggested that an increase in HDL and a decrease 
of monocytes had a positive effect on atherosclerosis, and 
the MHR value calculated by the ratio of monocyte count 
to HDL level could be a negative predictive marker for ath-
erosclerosis and cardiovascular diseases [5, 16]. MHR has 
been shown to be a prognostic factor for cardiovascular 
diseases [5, 16, 18]. MHR has also been reported to show 
asymptomatic organ damage, systemic inflammation and 
nephropathy in patients with hypertension [19, 20]. Usta 
et al. [8] and Vahit et al. [9], showed that MHR was a marker 
of metabolic syndrome characterized by obesity, increased 
glucose, blood pressure, LDL and decreased HDL. In a me-
ta-analysis and systematic review of 23 studies, Wekker 
et al. found that women with PCOS are more likely to be 
diagnosed with cardiometabolic risk factors such as Type 2 
diabetes mellitus and hypertension compared to women 
without PCOS. The authors also concluded that women with 
PCOS are at a higher risk of developing non-fatal cerebro-
vascular events. Sensitivity meta-analyses of high-quality 
studies have proven that the risk of developing Type 2 DM 
and HT are higher in women with PCOS  compared to those 
without PCOS [21]. In another meta-analysis, a slight cor-
relation was shown between biochemical parameters of 
hyperandrogenism and metabolic findings, while some 
correlation was found with these parameters and women 
Table 1. Comparison of mean values between polycystic ovary 




(n = 52) p
Mean SD Mean SD
Total cholesterol [mg/dL] 183.1 32.4 171.7 26.0 0.042
Monocyte/HDL ratio 12.5 4.6 10.4 4.0 0.010
Neutrophil/lymphocyte 
ratio 1.9 0.6 2.2 1.2 0.040
Lymphocyte/monocyte 
ratio 4.5 1.7 4.5 1.7 0.926
Age [years] 26.5 3.8 27.8 3.6 0.077
Glucose [mg/dL] 91.4 12.8 91.8 8.3 0.856
Insulin [μIU/mL] 11.9 7.2 9.3 5.8 0.033
LDL cholesterol [mg/dL] 118.6 29.5 108.6 27.0 0.066
Anti-Müllerian Hormon 
[mg/dL] 11.7 8.1 5.1 14.1 0.002
Trigliserid [mg/dL] 113.7 68.9 85.5 50.0 0.017
WBC [109/L] 7.5 1.7 7.2 2.1 0.352
Neutrophils [109/L] 4.2 1.2 4.2 1.2 0.960
Lymphocytes [109/L] 2.4 0.6 2.1 0.9 0.113
RBC [109/L] 6.0 1.8 4.5 0.3 < 0.001
MPV [fL] 7.7 0.9 8.0 1.0 0.085
HBa1c [mmol/mol] 5.4 0.4 5.5 0.3 0.432
PCOS — polycystic ovary syndrome; MHR — monocyte/high density 
lipoprotein ratio; LDL — low-density lioprotein; RBC — red blood cells; WBC 
— white blood cells; MPV — mean platelet volume; SD — standard deviation
(67.2% vs 40.4%) (p = 0.001). In addition, the rate of those with 
a MHR level ≥ 10.1 in the PCOS-obese group was significantly 
higher than the other groups (by combining groups) (84.8% 
vs 42.5%) (p < 0.001). In the logistic regression analysis, the 
determination of PCOS was increased by 3.026 folds (odds ratio; 
1.401–6.535) in predicting the presence of PCOS compared to 
those below 10.1, and 7.576 folds (odds ratio; 2.652–21.646) in 
predicting the presence of PCOS + obesity (Tab. 3).
Correlation analysis in PCOS patients revealed that 
MHR value was negatively correlated with age (p = 0.001; 
r = –0.412), LMR (p = 0.003; r = –0.377) and total cholesterol 
(p = 0.018; r = –0.302) (Tab. 4).
DISCUSSION
Polycystic ovarian syndrome is a syndrome that can af-
fect all body systems including the cardiovascular system 
[1, 2, 13]. Obesity, which is more common in patients with 
PCOS, also increases the cardiovascular risk [12–14]. While 
several studies in the literature [5, 6] have shown that MHR, 
which has been recently investigated, is an indicator of ath-
erosclerosis and cardiovascular disease, the present study 
demonstrated that MHR is significantly associated with both 
PCOS and the association between PCOS and obesity.
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with PCOS. A correlation was shown only with fT, insulin 
levels and insulin resistance, but it was reported that this 
correlation might be due to the well-known effect of insulin 
on SHBG and it was attributed to the possible limited effect 
of excess insulin on androgen ovarian production [22]. 
Increased inflammatory neutrophils cause the release 
of several types of cytokines, proteolytic enzymes, lead-




















PCOS + Lean Control + Obese Control + Lean
Figure 1. Clustering of MHL — monocytye/high-density lipoprotein 
values by groups; CI — confidence interval; HDL — high density 














Figure 2. In the receiver operating characteristic analysis, the 
threshold value of 10.1 for monocyte/high density lipprotein ratio 
was found to have a sensitivity of 84.8% and specificity of 58.5% in 
determining the association between polycystic ovary syndrome 
and obesity (AUC: 0.721; p < 0.001; LB: 0.628; UB: 0.814; CI 95%); ROC 
— receiver operating characteristic
Table 2. Comparison of average values between groups
PCOS-Obese PCOS-Lean Control-Obese Control-Lean Total
p
Mean SD Mean SD Mean SD Mean SD Mean SD
Age [years] 26.7 3.7 26.3 3.9 28.8 4.0 27.4 3.5 27.1 3.8 0.184
Monocyte/HDL ratio 13.9 4.8 11.4 3.9 10.3 4.1 10.4 4.0 11.5 4.4 0.004
Neutrophil/lymphocyte 
ratio 1.9 0.6 1.9 0.7 2.2 1.0 2.2 1.3 2.0 0.9 0.240
Lyphocyte/monocyte 
ratio 4.6 1.8 4.4 1.6 5.1 1.7 4.2 1.7 4.5 1.7 0.367
Total cholesterol [mg/dL] 186.3 31.7 179.0 33.5 175.5 20.4 170.2 28.1 178.0 30.2 0.146
Glucose [mg/dL] 92.6 15.5 89.8 8.0 94.6 5.4 90.6 9.1 91.5 11.0 0.480
Insulin [μIU/mL] 13.6 6.4 9.8 7.7 10.3 5.7 8.9 5.9 10.7 6.7 0.016
LDL Cholesterol [mg/dL] 115.3 27.6 122.6 31.6 113.6 23.6 106.5 28.4 114.1 28.7 0.169
Anti-Müllerian Hormon 
[mg/dL] 11.2 7.7 12.2 8.8 9.2 26.1 3.4 3.0 8.7 11.7 0.007
Triglyceride [mg/dL] 125.6 77.7 99.2 54.2 89.5 33.3 83.8 56.0 101.1 62.5 0.035
Neutrophils [109/L] 4.3 1.1 4.1 1.5 4.7 1.2 4.1 1.2 4.2 1.2 0.431
Lymphocytes [109/L] 2.4 0.6 2.3 0.6 2.3 0.7 2.1 0.9 2.3 0.7 0.238
Monocytes [109/L] 0.6 0.2 0.5 0.2 0.5 0.2 0.5 0.2 0.5 0.2 0.200
RBC [109/L] 6.1 1.9 6.0 1.7 4.6 0.4 4.5 0.3 5.3 1.5 < 0.001
WBC [109/L] 7.6 1.4 7.3 2.1 7.8 2.1 6.9 2.0 7.3 1.9 0.263
MPV [fL] 7.9 0.8 7.5 1.0 8.1 1.3 8.0 1.0 7.9 1.0 0.134
HBa1c [mmol/mol] 5.4 0.3 5.4 0.5 5.5 0.3 5.5 0.3 5.4 0.4 0.869
*p < 0.008 values were considered significant according to the Bonferroni correction; PCOS — polycystic ovary syndrome; MHR — monocyte/high density lipoprotein 
ratio; LDL — low-density lioprotein; RBC — red blood cells; WBC — white blood cells; MPV — mean platelet volume
tion cascade and impairment of endothelial integrity [23]. 
In response to inflammatory conditions, the number of 
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lymphocytes decreases, and it has been associated with 
adverse prognosis in coronary artery disease [24]. Activa-
tion of monocytes is associated with inflammation and 
atherosclerosis [25]. Monocytes and structurally altered 
macrophages trigger the production of other inflammatory 
cytokines [25, 26]. Systemic inflammation can be measured 
using various biochemical and hematological markers [27]. 
LMR has been proposed as a substitute marker for inflam-
mation in different populations, and also has a prognostic 
and predictive value [28, 29]. Yue et al. [30], investigated 
the neutrophil-lymphocyte ratio and the predictive value 
of the monocyte-lymphocyte ratio in diabetic retinopathy. 
In that study, no relationship was found between the sever-
ity of diabetic retinopathy and the monocyte/lymphocyte 
ratio, but the monocyte/lymphocyte ratio was found to be 
an independent risk factor for diabetic retinopathy [30]. 
Table 3. Comparison between groups by taking monocyte/high 




PCOS Control 0.004 3.026  (1.401–6.535)
n % n %
< 10.1 20 32.8 31 59.6
≥ 10.1 41 67.2 21 40.4
PCOS-Obese** Other groups < 0.001 7.576  (2.652–21.646)
< 10.1 5 15.2 46 57.5
≥ 10.1 28 84.8 34 42.5
*MHR groups are formed according to the threshold that the ROC analyze 
revealed the ghighest sensitivity and specificity; MHR — monocyte/high 
density lipoprotein ratio; PCOS — polycystic ovary syndrome; OR — odds 
ratio



















r 0.182 –0.377** –0.355**
p 0.149 0.003 0.004
Total cholesterol
r 0.072 –0.302* 0.074 0.172
p 0.570 0.018 0.559 0.175
Anti-Müllerian Hormon
r –0.070 –0.058 –0.301* 0.155 0.017
p 0.587 0.659 0.016 0.226 0.893
Triglyceride
r –0.190 0.303* 0.063 0.205 0.303* 0.019
p 0.140 0.020 0.627 0.110 0.017 0.885
BMI
r 0.221 0.161 –0.017 0.139 0.016 –0.020 0.214
p 0.079 0.214 0.896 0.275 0.900 0.878 0.095
WBC
r –0.126 0.190 0.360** 0.337** 0.202 –0.099 0.310*
p 0.319 0.142 0.004 0.006 0.110 0.442 0.014
Neutrophils
r –0.218 0.195 0.648** 0.138 0.116 –0.238 0.280*
p 0.083 0.131 < 0.001 0.277 0.363 0.060 0.027
Lymphocytes
r –0.033 0.183 –0.460** 0.671** 0.084 0.116 0.270*
p 0.794 0.159 < 0.001 < 0.001 0.508 0.366 0.034
Monocytes
r –0.302* 0.784** 0.084 –0.616** –0.174 –0.043 –0.053
p 0.015 < 0.001 0.508 < 0.001 0.169 0.738 0.683
RBC
r –0.185 –0.081 0.046 0.021 0.302* 0.435** 0.132
p 0.144 0.532 0.719 0.868 0.015 < 0.001 0.306
MPV
r 0.230 –0.223 0.051 0.137 0.166 0.028 –0.030
p 0.067 0.084 0.690 0.279 0.189 0.829 0.820
Homosistein
r –0.105 –0.001 –0.137 –0.019 –0.228 0.084 –0.129
p 0.411 0.996 0.282 0.883 0.070 0.513 0.316
HDL — high-density lioprotein; BMI — body mass index; WBC — white blood cells; RBC — red blood cells; MPV — mean platelet volume
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LMR has also been observed to be associated with vascular 
pathologies such as coronary artery disease and peripheral 
vascular disease [31]. As a result of our study, we found that 
MHR value was negatively correlated with LMR (p = 0.003; 
r = –0.377) in PCOS patients who are at cardiovascular risk. 
According to this finding, as LMR decreases, MHR value in-
creases significantly in patients with PCOS. In conclusion, our 
findings support that patients with PCOS can be followed 
up using LMR and MHR parameters for cardiovascular risk.
Dincgez-Cakmak et al. [7], found a significantly higher 
mean MHR  value in PCOS patients compared to the control 
group (9.6 vs 8.2) and reported a significant relationship 
between MHR and PCOS for the first time. However, these 
researchers additionally found that the mean MHR value in 
PCOS patients with metabolic syndrome was significantly 
higher than PCOS patients without metabolic syndrome, 
and stated that MHR value could be used as a predictive 
marker for metabolic syndrome in PCOS. For this reason, 
in our study in which we aimed to evaluate the relation-
ship between PCOS and MHR, patients with metabolic 
syndrome were excluded from the study. Usta et al. [13], 
found a significantly higher mean MHR value in patients 
with PCOS than the control group (11.5 and 8.8). In our study, 
the mean MHR in the PCOS group (12.5 ± 4.6) was signifi-
cantly higher than the control group (10.4 ± 4.0) (p = 0.01). 
In the ROC analysis conducted in our study, the sensitivity 
of a cut-off value of 10.1 for MHR was found as 84.8% and 
specificity as 58.5% in determining the association between 
PCOS and obesity (AUC: 0.721; p < 0.001; LB: 0.628; UB: 0.814; 
CI 95%). Accordingly, the rate of those who had a MHR 
level ≥ 10.1 in the PCOS group was found to be significantly 
higher than the control group (67.2% vs 40.4%) (p = 0.001). 
All these data show that MHR increases significantly in PCOS 
patients, especially MHR values  above 10.1 may have a high 
sensitivity rate in detection of patients with PCOS.
Usta et al. [13], calculated in their logistic regression 
analysis that the MHR value increased by 1.101 folds in-
creased determination power in predicting the presence 
of PCOS. In the logistic regression analysis performed in 
our study, it was calculated that there was a determination 
power of 3.026 folds (odds ratio; 1.401–6.535) in predicting 
the presence of PCOS in those with a MHR value ≥ 10.1. This 
finding shows that there is a clear relationship between 
MHR and PCOS.
Usta et al. [13], stated that MHR had an association 
not only with PCOS but also with obesity. These research-
ers divided the patients into four groups according to the 
presence of both PCOS and obesity, and found that 
the mean MHR was significantly higher in the PCOS-obese 
group than in all other groups. These researchers also found 
that the mean MHR in the obese control group was higher 
than the non-obese controls. In our study, according to 
the presence of both PCOS and obesity, the patients were 
divided into four groups and analyzed. Thirty-eight obese 
patients diagnosed with PCOS and 35 obese patients with-
out a diagnosis of PCOS were included in the study. Simi-
larly, in our study, the mean MHR value was found to be 
significantly higher in the PCOS-obese group compared 
to all other groups (p = 0.004). However, in our study, no 
difference was found between the other groups. This find-
ing might be resulted from the exclusion of patients with 
metabolic syndrome in our study. For this reason, all these 
data show that MHR level increases significantly in both 
those with PCOS and obesity independently from metabolic 
syndrome. When we excluded the metabolic syndrome, it 
seemed that only obesity does not have a direct effect on 
MHR. In addition, the fact that MHR value in non-obese 
PCOS is not different from non-PCOS groups suggests that 
obesity triggered by hormonal imbalance in PCOS causes 
a high increase in MHR value with PCOS.
In our study, the rate of those with a MHR level ≥ 10.1 was 
found to be significantly higher in the PCOS-obese group 
(84.8% vs 42.5%) (p < 0.001). In addition, in logistic regres-
sion analysis, it was found that there was a determinability of 
7,576 folds (odds ratio; 2.652–21.646) in predicting the pres-
ence of PCOS + obesity in those with a MHR value ≥ 10.1. These 
findings show that there is a significant relationship between 
the association of PCOS with obesity and MHR.
When the association of MHR with atherosclerosis and 
cardiovascular diseases [8] and the relationship between 
PCOS and obesity and dyslipidemia [31, 32] are evaluated, 
the fact that MHR has a significant association with both 
PCOS patients and PCOS-obese patients supports the view 
that the risk of atherosclerosis and cardiovascular is high 
with PCOS.
In our study, it was found that MHR value was negatively 
correlated with age in PCOS patients (p = 0.001; r = –0.412). 
According to this finding, as age increases, MHR value de-
creases significantly in patients with PCOS. In our study, 
the similar age distribution among the groups shows that 
the relationship between PCOS and MHR is not affected by the 
age factor. According to these findings, while interpreting 
the MHR value in patients with PCOS, it should be taken into 
consideration that the older age may decrease MHR, and 
cause an incorrect interpretation of the results.
There were some limitations in our study. Since our 
study was a cross-sectional study, the patients’ previous MHR 
values could not be learned, and the long-term changes in 
MHR could not be observed, because the patients were not 
prospectively monitored. In addition, since the long-term 
risks of cardiovascular diseases could not be observed, this 
subject could not be evaluated.  
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CONCLUSIONS
MHR is a practical, easy-to-apply, cost-effective and 
easily calculated indicator that requires no additional test-
ing for patients. Findings obtained from this study showed 
that MHR level was significantly associated with PCOS, and 
especially MHR values  above 10.1 could be a significant 
predictive marker of PCOS. Our study findings, in which the 
metabolic syndrome has been completely excluded, also 
showed that the association between PCOS and obesity is 
a very important trigger affecting MHR.
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